Epidemiology and risk factors for recurrence in biliary source bloodstream infection episodes in oncological patients

• Published in: Microbiology spectrum 2023-10, Vol.11 (5), p.e0214223-e0214223
• Main Authors: Grafia, Ignacio, Chumbita, Mariana, Seguí, Elia, Cardozo, Celia, Laguna, Juan Carlos, García de Herreros, Marta, Garcia-Pouton, Nicole, Villaescusa, Ana, Pitart, Cristina, Rico-Caballero, Verónica, Marco-Hernández, Javier, Zamora, Carles, Viladot, Margarita, Padrosa, Joan, Tuca, Albert, Mayor-Vázquez, Eric, Marco, Francesc, Martínez, Jose A., Mensa, Josep, Garcia-Vidal, Carolina, Soriano, Alex, Puerta-Alcalde, Pedro
• Format: Article
• Language: English
• Subjects: biliary source bloodstream infection; cholangitis; empirical treatment; mortality; recurrence
• ISSN: 2165-0497; 2165-0497
• DOI: 10.1128/spectrum.02142-23

We aimed to describe the characteristics and outcomes of biliary source bloodstream infections (BSIs) in oncological patients. Secondarily, we analyzed risk factors for recurrent BSI episodes. All episodes of biliary source BSIs in oncological patients were prospectively collected (2008–2019) and retrospectively analyzed. Logistic regression analyses were performed. A rule to stratify patients into risk groups for recurrent biliary source BSI was conducted. Four hundred biliary source BSIs were documented in 291 oncological patients. The most frequent causative agents were Escherichia coli (42%) and Klebsiella spp. (27%), and 86 (21.5%) episodes were caused by multidrug-resistant Gram-negative bacilli (MDR-GNB). The rates of MDR-GNB increased over time. Overall, 73 patients developed 118 recurrent BSI episodes. Independent risk factors for recurrent BSI episodes were prior antibiotic therapy (OR 3.781, 95% CI 1.906–7.503), biliary prosthesis (OR 2.232, 95% CI 1.157–4.305), prior admission due to suspected biliary source infection (OR 4.409, 95% CI 2.338–8.311), and BSI episode caused by an MDR-GNB (OR 2.857, 95% CI 1.389–5.874). With these variables, a score was generated that predicted recurrent biliary source BSI with an area under the receiver operating characteristic (ROC) curve of 0.819. Inappropriate empirical antibiotic treatment (IEAT) was administered in 23.8% of patients, and 30-d mortality was 19.5%. As a conclusion, biliary source BSI in oncological patients is mainly caused by GNB, with high and increasing MDR rates, frequent IEAT, and high mortality. Recurrent BSI episodes are frequent. A simple score to identify recurrent episodes was developed to potentially establish prophylactic strategies. This study shows that biliary source bloodstream infections (BSIs) in oncological patients are mainly caused by Gram-negative bacilli (GNB), with high and increasing rates of multidrug resistance. Importantly, recurrent biliary source BSI episodes were very frequent and associated with delays in chemotherapy, high rates of inappropriate empirical antibiotic therapy, and high 30-d mortality (19.5%). Using the variable independently associated with recurrent BSI episodes, a score was generated that predicted recurrent biliary source BSI with high accuracy. This score could be used to establish prophylactic strategies and lower the risk of relapsing episodes and the associated morbidity and mortality.